These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35264862)
1. A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin. Olatoke O; Zah V; Stanicic F; Vukicevic D; Yfantopoulos P; Thompson C; DeGeorge MK; Passik S Clinicoecon Outcomes Res; 2022; 14():119-128. PubMed ID: 35264862 [TBL] [Abstract][Full Text] [Related]
2. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza Gudin J J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888 [TBL] [Abstract][Full Text] [Related]
3. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza Brennan MJ; Kopecky EA; Marseilles A; O'Connor M; Fleming AB Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358 [TBL] [Abstract][Full Text] [Related]
5. Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation. Kucera SA; Zamloot MS; Crowley MM; Burns LH; Friedmann N; Barbier R J Opioid Manag; 2018; 14(6):429-436. PubMed ID: 30629279 [TBL] [Abstract][Full Text] [Related]
6. Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization. Petrilla A; Marrett E; Shen X; Kwong WJ; Pezalla E Am Health Drug Benefits; 2020 Feb; 13(1):21-31. PubMed ID: 32165996 [TBL] [Abstract][Full Text] [Related]
7. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694 [TBL] [Abstract][Full Text] [Related]
9. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255 [TBL] [Abstract][Full Text] [Related]
10. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study. Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238 [TBL] [Abstract][Full Text] [Related]
11. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population. Jewell J; Black J; Ellis M; Olsen H; Iwanicki J; Dart R Clin Drug Investig; 2023 Mar; 43(3):197-203. PubMed ID: 36859697 [TBL] [Abstract][Full Text] [Related]
12. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access. Webster L; Gudin J J Pain Res; 2024; 17():1989-2000. PubMed ID: 38854928 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480 [TBL] [Abstract][Full Text] [Related]
14. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Katz N; Kopecky EA; O'Connor M; Brown RH; Fleming AB Pain; 2015 Dec; 156(12):2458-2467. PubMed ID: 26262828 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone. Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986 [TBL] [Abstract][Full Text] [Related]
16. Nonmedical Use of Xtampza Green JL; Robbins RS; Dailey-Govoni T; Butler SF J Pain Res; 2021; 14():1773-1783. PubMed ID: 34163234 [TBL] [Abstract][Full Text] [Related]
17. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Hwang CS; Chang HY; Alexander GC Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216 [TBL] [Abstract][Full Text] [Related]
18. In Vitro Drug Release After Crushing: Evaluation of Xtampza Mayock SP; Saim S; Fleming AB Clin Drug Investig; 2017 Dec; 37(12):1117-1124. PubMed ID: 28940174 [TBL] [Abstract][Full Text] [Related]
19. Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective. Gadd S; Cox N; Samuelson J; Kenney A; Turner K; Cochran G Ther Drug Monit; 2021 Feb; 43(1):35-41. PubMed ID: 33278243 [TBL] [Abstract][Full Text] [Related]
20. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]